Consensus guidelines for antibacterial prophylaxis in patients with neutropenia

Area of Science:

• Oncology
• Infectious Diseases
• Microbiology

Background:

• The use of prophylactic antibiotics in neutropenic patients has been debated since 2011.
• Cancer therapies have evolved, including targeted therapies and immunotherapies, altering at-risk populations.
• Understanding of the microbiome's role in treatment response and antibiotic resistance has grown.

Purpose of the Study:

• To review recent evidence on antibacterial prophylaxis for neutropenic adults and children undergoing cancer therapy.
• To provide updated recommendations for the Australian and New Zealand healthcare settings.
• To evaluate the benefits and harms of antibiotic prophylaxis in the context of evolving medical knowledge and patient populations.

Main Methods:

• Systematic review of current evidence on antibacterial prophylaxis in neutropenic cancer patients.
• Evaluation of benefits (infection reduction) versus harms (antimicrobial resistance, adverse effects, microbiome disruption).
• Consideration of the current Australian and New Zealand healthcare context and improved sepsis pathway management.

Main Results:

• In most cases, the harms of antibiotic prophylaxis (resistance, side effects, microbiome disruption) outweigh the benefits.
• Antibiotic prophylaxis did not demonstrate a mortality benefit in the reviewed evidence.
• Improved management of neutropenic fever through sepsis pathways reduces the need for routine prophylaxis.

Conclusions:

• Antibacterial prophylaxis is generally not recommended for neutropenic cancer patients in Australia and New Zealand.
• The potential for increased antimicrobial resistance and adverse effects is a significant concern.
• Focus should remain on evidence-based management of neutropenic fever and judicious antibiotic use.